The global spine biologics market is expected to reach $30.43 billion by 2034 due to factors including increased prevalence of spinal disorders, growing preference for minimally invasive procedures and favorable reimbursement policies.
In 2023, the spine biologics market was valued at $5.16 billion.
North America is expected to see the highest revenue share for spine biologics during the forecast period, and the Asia Pacific region is expected to grow at the fastest CAGR.
Key players identified by the research group include Medtronic, Stryker, Zimmer Biomet and Bioventus.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.